Viral persistence: HIV's strategies of immune system evasion

Annual Review of Medicine

Volumn 53, Issue , 2002, Pages 499-518

  Johnson, Welkin E ^a   Desrosiers, Ronald C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AIDS vaccine; Antigenic escape; Lentivirus; Neutralizing antibody; SIV

Indexed keywords

ANTIGEN; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEF PROTEIN; NEUTRALIZING ANTIBODY; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOTOXIC T LYMPHOCYTE; GLYCOSYLATION; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRINAE; NONHUMAN; PATHOGENESIS; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS DNA CELL DNA INTERACTION; VIRUS ENVELOPE; VIRUS REPLICATION; ANIMAL; ANTIGENIC VARIATION; CLONAL ANERGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIGENIC VARIATION; CLONAL ANERGY; GENE PRODUCTS, NEF; HIV INFECTIONS; HUMANS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 0036181249     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.53.082901.104053     Document Type: Review

References (133)

1. Persistence of viruses
2. Reverse transcriptase and the generation of retroviral DNA
3. The fidelity of retroviral reverse transcriptases
4. High mutation rate of a spleen necrosis virus-based retrovirus vector
5. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase
6. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
7. HIV-1 variation diminishes CD4 T lymphocyte recognition
8. Endogenous ecotropic and recombinant MCF mouse retroviral variation and escape from antiviral CTL
9. A single residue exchange within a viral CTL epitope alters proteasomemediated degradation resulting in lack of antigen presentation
10. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo
11. T cell responses and viral escape
12. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
13. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
14. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
15. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
16. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine
17. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
18. Definition of five new simian immunodeficiency virus cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I molecules: Evidence for an influence on disease progression
19. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
20. Escape of human immunodeficiency virus from immune control
21. AIDS. Escape from the immune system
22. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
23. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
24. Protection of macaques against vaginal transmission of a pathogenic HIV- 1/SIV chimeric virus by passive infusion of neutralizing antibodies
25. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site
26. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
27. Characterization of HIV-1 neutralization escape mutants
28. Change in tropism upon immune escape by human immunodeficiency virus
29. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12
30. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene
31. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1
32. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites
33. Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop
34. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp 120 glycoprotein conferred by a gp41 amino acid change
35. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes
36. Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus
37. Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection
38. Antigenic variation in visna virus
39. B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins
40. A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization
41. Neutralization of feline immunodeficiency virus by polyclonal feline antibody: Simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoprotein
42. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: Isolation of a neutralization escape variant
43. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees
44. Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course
45. Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker
46. Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers
47. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera
48. Autologous HIV-1 neutralizing antibodies: Emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies
49. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors
50. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera
51. Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection
52. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys
53. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus
54. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys
55. Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence
56. HIV entry and its inhibition
57. Structural basis for membrane fusion by enveloped viruses
58. A vaccine for HIV type 1: The antibody perspective
59. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
60. HIV-1 antibody - Debris or virion?
61. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
62. HIV-1 membrane fusion: Targets of opportunity
63. Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation
64. Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype
65. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain
66. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4
67. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein
68. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication
69. CD4-independent infection by HIV-2 (ROD/B): Use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry
70. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization
71. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
72. Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region
73. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules
74. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein
75. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants
76. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: Correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4
77. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein
78. The antiviral activity of antibodies in vitro and in vivo
79. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS
80. Structure and function in recombinant HIV-1 gp120 and speculation about the disulfide bonding in the gp120 homologs of HIV-2 and SIV
81. Hypothetical assignment of intrachain disulfide bonds for HIV-2 and SIV envelope glycoproteins
82. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells
83. The antigenic structure of the HIV gp 120 envelope glycoprotein
84. Structure of an HIV gp 120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
85. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp 120 envelope glycoprotein
86. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades
87. Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques
88. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization
89. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer
90. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies
91. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation
92. A role for carbohydrates in immune evasion in AIDS
93. HIV-I: Fifteen proteins and an RNA
94. Identification of highly attenuated mutants of simian immunodeficiency virus
95. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients
96. Importance of the nef gene for maintenance of high virus loads and for development of AIDS
97. Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection
98. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection
99. Interactions of HIV-1 NEF with cellular signal transducing proteins
100. HIV-1 Nef and host cell protein kinases
101. Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 downregulation
102. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules
103. Two elements target SIV Nef to the AP-2 clathrin adaptor complex, but only one is required for the induction of CD4 endocytosis
104. Mechanism of Nef-induced CD4 endocytosis: Nef connects CD4 with the mu chain of adaptor complexes
105. Viral strategies of immune evasion
106. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance
107. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens
108. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes
109. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins
110. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis
111. HIV- 1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
112. HIV's evasion of the cellular immune response
113. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein
114. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells
115. The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes
116. Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking
117. Simian and human immunodeficiency virus Nef proteins use different surfaces to downregulate class I major histocompatibility complex antigen expression
118. Population biology of HIV-1 infection: Viral and CD4+ T cell demographics and dynamics in lymphatic tissues
119. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
120. Viral dynamics in human immunodeficiency virus type 1 infection
121. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-and SIV-infected lymph nodes
122. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition
123. HIV type 1-specific helper T cells: A critical host defense
124. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV- 1 infection, but decline with prolonged viral suppression
125. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals
126. Immune control of HIV-1 after early treatment of acute infection
127. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
128. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
129. Reservoirs for HIV-I: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy
130. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
131. Viral dynamics in HIV-1 infection
132. The challenge of viral reservoirs in HIV-1 infection
133. The immunology of vaccination